Claims

1. Use of a combination of a bupropion and a dextromethorphan in the manufacture of a medicament for treating nicotine addiction, wherein the medicament is to be administered to a person suffering from nicotine addiction once daily or twice daily for at least 14 consecutive days, wherein the person receives a total daily dose of about 60 mg to about 100 mg of the dextromethorphan and about 200 mg to about 250 mg of the bupropion, and wherein the treatment is more effective than administering the same amount of the bupropion without the dextromethorphan.

2. The use of claim 1, wherein the combination of the bupropion and the dextromethorphan is to be administered to the person daily for at least 30 consecutive days.

3. The use of claim 1, wherein the combination of the bupropion and the dextromethorphan is to be administered to the person daily for at least 60 consecutive days.

4. The use of claim 1, wherein about 100 mg to about 125 mg of the bupropion in each dose is to be administered to the person twice daily.

5. The use of claim 1, wherein about 200 mg to about 250 mg of the bupropion is to be administered daily to the person in two divided doses.

6. The use of claim 1, wherein about 105 mg of the bupropion in each dose is to be administered to the person twice daily.

7. The use of claim 1, wherein about 60 mg to about 100 mg of the dextromethorphan is to be administered daily to the person in two divided doses.

8. The use of claim 1, wherein about 30 mg to about 40 mg of the dextromethorphan in each dose is to be administered to the person twice daily.

9. The use of claim 1, wherein about 40 mg to about 50 mg of the dextromethorphan in each dose is to be administered to the person twice daily.

10. The use of claim 1, wherein about 44 mg to about 46 mg of the dextromethorphan in each dose is to be administered to the person twice daily.

11. The use of claim 10, wherein the use is more effective in reducing nicotine consumption than administering the same amount of the dextromethorphan alone.

12. The use of claim 1, wherein the use is more effective in reducing nicotine consumption than administering the same amount of the dextromethorphan alone.

13. The use of claim 1, wherein about 105 mg of the bupropion is to be administered to the person twice daily for at least 30 days.

14. The use of claim 1, wherein about 45 mg of the dextromethorphan is to be administered to the person twice daily for at least 30 days.

15. The use of claim 1, wherein about 105 mg of the bupropion and about 45 mg of the dextromethorphan are to be co-administered to the person twice daily for at least 30 days.

16. The use of claim 13, 14, or 15, wherein the use is more effective in reducing nicotine consumption, as measured on day 30 of treatment, than a control use, wherein the control use consists of administering 105 mg of the bupropion alone to the person twice daily for 30 days.

17. The use of claim 1, wherein about 105 mg of the bupropion is to be administered

to the person twice daily for at least 60 days.

18. The use of claim 1, wherein about 45 mg of the dextromethorphan is to be administered to the person twice daily for at least 60 days.

19. The use of claim 1, wherein about 105 mg of the bupropion and about 45 mg of the dextromethorphan are to be co-administered to the person twice daily for at least 60 days.

20. The use of claim 17, 18, or 19, wherein the use is more effective in reducing nicotine consumption, as measured on day 30 of treatment, than a control use, wherein the control use consists of administering 105 mg of the bupropion alone to the person twice daily for 30 days.

21. The use of claim 1, the combination of the bupropion and the dextromethorphan is to be administered once daily to a person suffering from nicotine addiction for at least 14 consecutive days, wherein the person receives a total daily dose of about 60 mg to about 100 mg of the dextromethorphan and about 200 mg to about 250 mg of the bupropion, and wherein the treatment is more effective than administering the same amount of the bupropion without the dextromethorphan.

22. The use of claim 1, wherein the bupropion has an enantiomeric excess of the R-enantiomer that is at least 90%.

23. The use of claim 1, wherein the bupropion has an enantiomeric excess of the S-enantiomer that is at least 90%.

24. The use of claim 1, wherein the bupropion is deuterium enriched.

25. The use of claim 1, wherein the dextromethorphan is deuterium enriched.